Abstract
We have used the inhibition of binding of a potent β antagonist, iodohydroxybenzylpindolol, to canine lung-plasma membrane β-adrenergic receptors as a test for β-blocking autoantibodies in the sera of 376 mildly and severely asthmatic children. This binding inhibition assay, coupled with a variant test in which the binding assay was performed on selected sera (binding values below 2 SD from the mean) before and after immunodepletion of the sera (removal of IgG and IgA), permitted the conclusion that about 5% of the juvenile asthmatic population studied produce β-blocking autoantibodies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
